Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
Study to be presented at the
More than 198,000 patients are diagnosed with non-small cell lung cancer (NSCLC) each year. An estimated 3-9% of those patients will develop leptomeningeal carcinomatosis (LMC), a complication in which the cancer spreads to the membranes surrounding the brain and spinal cord. LMC is typically diagnosed through clinical evaluation, imaging and cytology, which have limited sensitivity. When left untreated, the average patient life expectancy is just four to six weeks.
The retrospective study, conducted at the
“LMC is a devastating diagnosis for patients and, quite often, hospice is the only recommended course of action,” said
“Identifying actionable mutations is critical for treating patients with LMC,” said
The study, titled “Beyond Cytology – A Single Institution Experience Using CNSide™ for Diagnosing and Monitoring Treatment Response in Non-Small Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis (LMC),” can be accessed here.
Forward-Looking Statements Disclaimer
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” "will," "designed," and "potential" or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements regarding the ability of CNSide to identify actionable mutations in lung cancer patients with LMC that allow for targeted treatment decisions that may improve outcomes and extend life expectancy, the ability of CNSide cerebrospinal fluid assay to diagnose cancer that has metastasized to the central nervous system and the ability of Biocept’s molecular diagnostic assays to provide physicians with clinically actionable information to aid in the diagnosis, treatment and monitoring of patients with cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including the risk that our products and services may not perform as expected. These and other risks are described in greater detail under the "Risk Factors" heading of our Quarterly Report on Form 10-Q for the quarter ended